AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
5min chapter
Episode 21. Newly Diagnosed Mantle Cell Lymphoma
Blood Cancer Talks
The Effect of Bena Mustin on PFS and Overall Survival
FDA recently requested manufacturer to withdraw a brute-nebs mantles of lymphoma and marginal zol lymphoma indication. So, obviously, you're not based in the US, but what do you think of this decision of the FDA? Well, we have some advantages and some disadvantages in Europe. And our advantage is that my brute-neb was not withdrawn from the European market, so we can still work on that. The disadvantage is, in comparison to the US, you have at least two other VDKIs registered in Montesellen-Foma which are our color-bruitinib and Zano- bruitinib. But it's a bizarre situation because
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode